ArticleBMC musculoskeletal disorders2013
Effects of salubrinal on development of osteoclasts and osteoblasts from bone marrow-derived cells.
Article in BMC musculoskeletal disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Locally delivered dexpanthenol enhances bone regeneration in a rabbit defect model: Implications for oral and maxillofacial surgery.BMC oral health · 2026Article
- The role of the unfolded protein response pathway in bone homeostasis and potential therapeutic target in cancer-associated bone disease.Bone research · 2025Review
- Bone and the Unfolded Protein Response: In Sickness and in Health.Calcified tissue international · 2023Review
- ER Stress, the Unfolded Protein Response and Osteoclastogenesis: A Review.Biomolecules · 2023Review
- The oral microbiome in young women at different stages of periodontitis:Frontiers in cellular and infection microbiology · 2022Article
- Mechanical loading attenuates breast cancer-associated bone metastasis in obese mice by regulating the bone marrow microenvironment.Journal of cellular physiology · 2021Article
- Salubrinal Exposes Anticancer Properties in Inflammatory Breast Cancer Cells by Manipulating the Endoplasmic Reticulum Stress Pathway.Frontiers in oncology · 2021Article
- Phosphorylation of eIF2α signaling pathway attenuates obesity-induced non-alcoholic fatty liver disease in an ER stress and autophagy-dependent manner.Cell death & disease · 2020Article
- Knee loading repairs osteoporotic osteoarthritis by relieving abnormal remodeling of subchondral bone via Wnt/β-catenin signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- eIF2α signaling regulates autophagy of osteoblasts and the development of osteoclasts in OVX mice.Cell death & disease · 2019Article
- Wnt3a involved in the mechanical loading on improvement of bone remodeling and angiogenesis in a postmenopausal osteoporosis mouse model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling.International journal of oncology · 2018Article
- GLUCOCORTICOID EXCESS IN BONE AND MUSCLE.Clinical reviews in bone and mineral metabolism · 2018Article
- eIF2α signaling regulates ischemic osteonecrosis through endoplasmic reticulum stress.Scientific reports · 2017Article
- The unfolded protein response in skeletal development and homeostasis.Cellular and molecular life sciences : CMLS · 2016Review
- Guanabenz Downregulates Inflammatory Responses via eIF2α Dependent and Independent Signaling.International journal of molecular sciences · 2016Article
- Knee loading inhibits osteoclast lineage in a mouse model of osteoarthritis.Scientific reports · 2016Article
- Article
- Article
- Chondroprotective effects of Salubrinal in a mouse model of osteoarthritis.Bone & joint research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoporosis is a skeletal disease leading to an increased risk of bone fracture. Using a mouse osteoporosis model induced by administration of a receptor activator of nuclear factor kappa-B ligand (RANKL), salubrinal was recently reported as a potential therapeutic agent. To evaluate the role of salubrinal in cellular fates as well as migratory and adhesive functions of osteoclast/osteoblast precursors, we examined the development of primary bone marrow-derived cells in the presence and absence of salubrinal. We addressed a question: are salubrinal's actions more potent to the cells isolated from the osteoporotic mice than those isolated from the control mice?
methodsUsing the RANKL-injected and control mice, bone marrow-derived cells were harvested. Osteoclastogenesis was induced by macrophage-colony stimulating factor and RANKL, while osteoblastogenesis was driven by dexamethasone, ascorbic acid, and β-glycerophosphate.
resultsThe results revealed that salubrinal suppressed the numbers of colony forming-unit (CFU)-granulocyte/macrophages and CFU-macrophages, as well as formation of mature osteoclasts in a dosage-dependent manner. Salubrinal also suppressed migration and adhesion of pre-osteoclasts and increased the number of CFU-osteoblasts. Salubrinal was more effective in exerting its effects in the cells isolated from the RANKL-injected mice than the control. Consistent with cellular fates and functions, salubrinal reduced the expression of nuclear factor of activated T cells c1 (NFATc1) as well as tartrate-resistant acid phosphatase.
conclusionsThe results support the notion that salubrinal exhibits significant inhibition of osteoclastogenesis as well as stimulation of osteoblastogenesis in bone marrow-derived cells, and its efficacy is enhanced in the cells harvested from the osteoporotic bone samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.